Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*
Critical Care Medicine2019Vol. 47(5), pp. 632–642
Citations Over TimeTop 1% of 2019 papers
Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende, Derek C. Angus, Lyle L. Moldawer, Elliott D. Crouser, Greg S. Martin, Craig M. Coopersmith, Scott C. Brakenridge, Florian Mayr, Pauline K. Park, June Ye, Ian M. Catlett, Ihab Girgis, Dennis M. Grasela
Abstract
In this first clinical evaluation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days. Further randomized trials on programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition are needed to evaluate its clinical safety and efficacy in patients with sepsis.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Ιστορική εξέλιξη της έννοιας του placebo από τα μέσα του 19ου αιώνα μέχρι σήμερα(2006)
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)